What is the recommended treatment for ipilimumab‑induced diarrhea?

Treatment of Ipilimumab-Induced Diarrhea

For ipilimumab-induced diarrhea, initiate high-dose systemic corticosteroids (0.5-2 mg/kg prednisone equivalent daily) after excluding infectious causes, and escalate to infliximab or vedolizumab for steroid-refractory cases. 1

Initial Assessment and Workup

Before starting immunosuppressive therapy, you must exclude infectious etiologies:

• Obtain stool cultures, C. difficile testing, and parasitic studies to rule out infectious causes of diarrhea 1, 2
• Measure fecal lactoferrin and calprotectin in patients with grade ≥2 diarrhea (>4 bowel movements above baseline) to stratify risk and determine urgency of endoscopic evaluation 1
• Consider endoscopic confirmation before initiating high-dose systemic corticosteroids, particularly to assess severity 1
• Abdominal imaging should be reserved for patients with dominant pain, fever, or bleeding—not routinely performed for diarrhea alone 1

Treatment Algorithm by Severity

Grade 1 Diarrhea (Mild)

• Symptomatic management with antidiarrheal agents (loperamide or codeine) is often sufficient 3, 4
• Conservative therapy alone is advised; avoid immunosuppressants including topical budesonide due to lack of efficacy data 2
• Monitor closely as progression can occur rapidly, particularly with ipilimumab 1

Grade 2-4 Diarrhea (Moderate to Severe)

First-line: Systemic Corticosteroids

• Initiate prednisone 0.5-2 mg/kg daily (or IV methylprednisolone equivalent) 1, 2
• Hold ipilimumab therapy during treatment 2, 4
• Taper steroids over 4-6 weeks once symptoms resolve 1
• Response rates to corticosteroids alone are approximately 50% 3

Second-line: Biologic Therapy for Steroid-Refractory Disease

• Infliximab 5 mg/kg is highly effective for steroid-refractory colitis, with 100% response rates in some series 3, 5
• Vedolizumab is an equally effective alternative to infliximab 1, 6
• Most patients respond to a single dose of infliximab, though some may require multiple doses 7

Critical Timing Considerations

Rapid progression of ipilimumab-induced colitis can occur within days, making prompt diagnosis and treatment essential 1. The median time to diarrhea onset is after 2 ipilimumab infusions (range 1-4) 5, 4. An accelerated treatment approach with early methylprednisolone followed by prompt infliximab addition for non-responders achieved symptom resolution in 74% of patients within a median of 8.5 days 8.

Special Considerations

Budesonide

• Budesonide is ineffective for prophylaxis of ICI colitis 1
• May be used specifically for ICI-associated microscopic colitis 1
• High-dose budesonide (9-12 mg daily) has shown some efficacy as a steroid-sparing agent in small series, but requires further study 4

Refractory Cases

• Despite infliximab therapy, 33% of patients with severe colitis may require surgical intervention 7
• Bowel perforation and toxic megacolon are life-threatening complications requiring urgent surgical consultation 9
• If diarrhea remains unresponsive after corticosteroids and biologics, investigate for alternative diagnoses 8

Resumption of Immunotherapy

Patients who develop ICI colitis may be retreated with immunotherapy under select conditions after resolution of symptoms and completion of steroid taper 1. Most patients in accelerated treatment protocols were able to continue their planned immunotherapy after diarrhea control 8.

Common Pitfalls

• Do not delay treatment waiting for endoscopy in patients with severe symptoms—ipilimumab colitis progresses rapidly 1
• Avoid using corticosteroids for low-grade diarrhea without clear evidence of colitis, as this risks overtreatment, particularly with ICI-chemotherapy combinations 6
• Do not assume all diarrhea is immune-mediated—infectious workup is mandatory before immunosuppression 1, 2
• Consider early escalation to infliximab rather than prolonged high-dose steroids, given the disappointing 50% response rate to steroids alone 3